Skip to main content
. 2015 Jan 29;13(4):666–668. doi: 10.2450/2015.0224-14

Figure 1.

Figure 1

Figure 1a - Interference of Dabigatran with a prothrombinase base assay for APCr detection.

Figure 1b - Interference of Rivaroxaban with a prothrombinase base assay for APCr detection.

We considered seven FVL heterozygous subjects. In patients (three) treated with Dabigatran basal APCr ratio was 1.67+0.31, APCr ratio observed during treatment was 2.87+0.29. This difference was statistically significant (p<0.01).

In patients (four) treated with Rivaroxaban basal APCr ratio was 1.81+0.27, APCr ratio observed during treatment was 1.31+0.21. This difference was statistically significant (p<0.05).

APCr: activated protein C resistance.